Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma

Sponsor
Peking University
Study ID
NCT04705519
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is an open-label, phase II study evaluating efficacy and safety of Nab-paclitaxel Combined With Bevacizumab for unresectable Recurrent or metastatic extrapulmonary neuroendocrine carcinoma.

Key Dates

First listed
Jan 12, 2021
Start date
Jan 5, 2021
Status verified
Sep 2024
Primary completion
Sep 30, 2024
Completion
Sep 30, 2024

Study Design

Enrollment
79 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Nab-paclitaxel Combined With Bevacizumab
    Nab-paclitaxel, Bevacizumab

Primary Outcome Measure

Overall Survival (OS) [ Time Frame: an expected average of 24 months ]

Related Studies